
Takeda Plans New Plant for Plasma-derived Therapies
Japanese drugmaker Takeda plans to invest about $765 million to build a new manufacturing facility in Osaka for plasma-derived therapies (PDTs). The company said the sum is the largest-ever investment to expand capacity in Japan and the plant will also be the biggest of its kind in the country.